TREK1 channel activation as a new analgesic strategy devoid of opioid adverse effects.

Jérôme BusserollesIsmail Ben SoussiaLaetitia PoucholNicolas MarieMathieu MeleineMaïly DevilliersCéline JudonJulien SchoppLoïc ClémenceauLaura PouponEric ChapuySerge RichardFlorence NobleFlorian LesageSylvie DuckiAlain EschalierStéphane Lolignier

Published in: British journal of pharmacology (2020)

This proof-of-concept study shows that TREK1 activators could constitute a novel class of painkillers, inspired by the mechanism of action of opioids but devoid of their adverse effects.

Keyphrases

chronic pain
pain management
neuropathic pain
anti inflammatory
spinal cord injury